Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Sermorelin

GHRH (1-29), GRF 1-29 NH2, Sermorelin acetate

Quick Stats
Studies 223
Trials 41
Score 3
1996 pubmed

Growth hormone (GH)-releasing hormone-induced GH response in hypothalamic amenorrhea: evidence of altered central neuromodulation.

Genazzani. A D AD; Petraglia. F F; Gastaldi. M M; Gamba. O O; Corazza. F F; D'Ambrogio. G G; Genazzani. A R AR

Key Findings

  • GH‑RH (sermorelin) induced a higher maximal GH release and larger AUC in weight‑loss‑related amenorrhea patients than in controls
  • Basal IGF‑I and BMI were lower in amenorrheic patients
  • No significant correlation between BMI and IGF‑I or LH and IGF‑I

Practical Outcomes

  • Sermorelin can still trigger GH spikes in low‑BMI individuals, but it may not raise IGF‑1 without addressing nutrition and body weight. Biohackers should prioritize restoring healthy weight and IGF‑1 before relying on GH‑releasing peptides for performance or longevity benefits.

Summary

In women who stopped menstruating because they lost weight, a GH‑releasing hormone test (like sermorelin) caused a bigger GH surge than in healthy women, but their IGF‑1 levels stayed low, showing the GH system is out of balance when body weight is low.

Abstract

To evaluate the GH-releasing hormone (GH-RH)-induced response of GH in patients affected by hypothalamic amenorrhea. Patients affected by weight-loss-related hypothalamic amenorrhea (n = 28) were studied and compared with 20 healthy controls. Among patients with weight-loss amenorrhea, both hypogonadotropic and normogonadotropic conditions were present. All subjects underwent a GH-RH test (GEREF, Sereno, Rome, Italy) (1 microgram/kg body weight IV). Plasma GH concentrations were determined using commercially available RIAs. Also, in selected samples insulin-like growth factor-I (IGF-I) levels were measured. Basal plasma IGF-I levels as well as body mass index (BMI) were lower in amenorrheic patients than in healthy controls. No significant correlation was found between BMI and IGF-I or E2 plasma levels or between LH and IGF-I plasma levels. The basal GH plasma levels were comparable in all groups of subjects. The GH-RH--induced GH response evaluated as maximal release and as area under the curve (AUC) was higher in amenorrheic patients than in control subjects. The amenorrheic condition associated with reduced BMI changes the GH-RH--induced GH response in hypothalamic amenorrhea, supporting a GH and a IGF-I disregulation in weight-loss--related amenorrhea.

Study Information

Provider

pubmed

Year

1996